 Alterity Therapeutics ASX: ATH, NASDAQ: ATHE Alterity or the Company today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 formerly PBT434 has been selected for presentation at the 2020 International Congress of Parkinsons Disease and Movement Disorders MDS 2020 and the American Neurological Associations 2020 Annual Meeting ANA 2020. 